文献速递妇科

帕博利珠单抗联合仑伐替尼作为错配修复功能完整晚期子宫内膜癌患者一线治疗:基于美国的成本-效果分析

Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
PubMed 文献 · Gynecol Oncol · 2022-07-01

本研究基于KEYNOTE-775研究,采用7年Markov模型纳入697例错配修复功能完整(pMMR)晚期子宫内膜癌(aEC)患者,比较帕博利珠单抗联合仑伐替尼(PL)与化疗的成本-效果。以每QALY 15万美元为支付意愿阈值,PL较化疗增量成本38,582美元、增量0.349 QALY,增量成本效果比(ICER)为每QALY 110,401美元。作者认为从美国经济角度看,PL方案可能最具成本-效果。

要点

  • 模型纳入697例pMMR晚期子宫内膜癌患者,比较PL与化疗7年成本-效果。
  • PL较化疗增量成本38,582美元,增量0.349 QALY,ICER每QALY 110,401美元。
  • 支付意愿阈值每QALY 15万美元时,约79.2%模拟中PL具有成本-效果。

核心结论

  • 对于pMMR晚期子宫内膜癌患者,从美国经济角度看,在支付意愿阈值每QALY 15万美元时,PL方案可能是最具成本-效果的策略。

研究设计与样本

  • 成本-效果分析,基于Markov模型,纳入697例患者,评估PL与化疗7年内的总成本、生命年(LYs)、质量调整生命年(QALYs)和增量成本效果比(ICER),支付意愿阈值为每QALY 15万美元,并进行单因素、双因素和概率敏感性分析及亚组分析。

主要发现

  • 化疗组每例患者平均生存0.705 QALY(0.901 LY),平均成本163,777美元。
  • PL组较化疗组增量成本38,582美元,额外获得0.349 QALY。
  • PL组较化疗组ICER为每QALY 110,401美元。
  • 帕博利珠单抗的成本对ICER有显著影响。
  • 在支付意愿阈值每QALY 15万美元时,约79.2%的模拟中PL具有成本-效果;亚组分析显示,对于既往接受过1线治疗的患者,PL是最具成本-效果的方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2022, the KEYNOTE-775 (NCT03517449) study showed that pembrolizumab plus lenvatinib (PL) has more benefits than traditional chemotherapy as a first-line regimen to treat patients with mismatch repair-proficient (pMMR) advanced endometrial cancer (aEC). However, given the high cost of immuno-targeted therapy, the widespread use among patients remains uncertain. Therefore, we conducted a cost-effectiveness comparison between PL and chemotherapy. METHODS: We evaluated the cost-effectiveness of PL versus chemotherapy over 7 years by developing a comprehensive Markov model, included 697 patients, that calculated total cost, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) at a willingness-to-pay (WTP) threshold of $150,000 per QALY. The robustness of the model was evaluated by one-way, two-way, and probabilistic sensitivity analyses. In addition, we also performed subgroup analyses. RESULTS: Chemotherapy yielded a mean survival of 0.705 QALYs (0.901 LYs) per patient and was associated with a mean cost of $163,777. PL was associated with an incremental cost of $38,582 and an additional 0.349 QALYs, leading to an ICER of $110,401 per QALY as compared to chemotherapy. The cost of pembrolizumab had a significant impact on ICER. At the assumed WTP threshold of $150,000 per QALY, approximately 79.2% of simulations show cost-effectiveness occurs in PL. Results of the subgroup analysis showed that PL was the most cost-effective regimen for patients who had previously received 1-line of therapy. CONCLUSION: For patients with pMMR aEC, the PL strategy may be the most cost-effective strategy at a WTP of $150,000 from the economic perspective of the United States.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu K, Zhu Y, Zhou Y, et al. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. Gynecol Oncol. 2022. PMID: 35781166. doi:10.1016/j.ygyno.2022.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。